Drug
ORIC-101
ORIC-101 is a pharmaceutical drug with 5 clinical trials. Currently 1 active trials ongoing. Historical success rate of 50.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
50.0%
Based on 2 completed trials
Completion Rate
50%(2/4)
Active Trials
1(20%)
Results Posted
0%(0 trials)
Terminated
2(40%)
Phase Distribution
Ph phase_1
5
100%
Phase Distribution
5
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 1Safety & dosage
5(100.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
50.0%
2 of 4 finished
Non-Completion Rate
50.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
5
all time
Status Distribution
Active(1)
Completed(2)
Terminated(2)
Detailed Status
Terminated2
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
5
Active
1
Success Rate
50.0%
Most Advanced
Phase 1
Trials by Phase
Phase 15 (100.0%)
Trials by Status
recruiting120%
terminated240%
completed240%
Recent Activity
1 active trials
Showing 5 of 5
recruitingphase_1
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT05652920
terminatedphase_1
Study of ORIC-101 in Combination With Anticancer Therapy
NCT03928314
terminatedphase_1
Study of ORIC-101 in Combination With Enzalutamide
NCT04033328
completedphase_1
Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects
NCT03835637
completedphase_1
Study of ORIC-101 in Healthy Adult Subjects
NCT03324555
Clinical Trials (5)
Showing 5 of 5 trials
NCT05652920Phase 1
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NCT03928314Phase 1
Study of ORIC-101 in Combination With Anticancer Therapy
NCT04033328Phase 1
Study of ORIC-101 in Combination With Enzalutamide
NCT03835637Phase 1
Single and Multiple Dose Study of ORIC-101 in Adult Healthy Subjects
NCT03324555Phase 1
Study of ORIC-101 in Healthy Adult Subjects
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5